Rescue therapy in malignant atrophic papulosis: a new era of promising treatments targeting interferon and complement pathways
- PMID: 40127150
- DOI: 10.1093/bjd/ljaf106
Rescue therapy in malignant atrophic papulosis: a new era of promising treatments targeting interferon and complement pathways
Conflict of interest statement
Conflicts of interest: D.S.-S. has received consulting fees from AstraZeneca, Eli Lilly, GSK, Pfizer and Sanofi, and research grants from AstraZeneca and Pfizer. D.L. has received consulting fees from AstraZeneca, Biocryst, CSL Behring and Takeda. E.H. has received consulting fees from AstraZeneca, GSK, Pfizer, Roche/Chugai and Sanofi Genzyme. E.L. has received consulting fees from AstraZeneca and GSK. (All consulting fees were less than €10 000.) The remaining authors declare no conflicts of interest.
Comment in
-
Malignant atrophic papulosis: which is the primary driver - interferon or complement overactivation?Br J Dermatol. 2025 Jun 20;193(1):10. doi: 10.1093/bjd/ljaf148. Br J Dermatol. 2025. PMID: 40241648 No abstract available.
LinkOut - more resources
Full Text Sources
